Intuitive Surgical, Inc. (ISRG) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $397.72. The rating moved from Overbought to Neutral on August 19, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$397.72
• Last changeMoved from Overbought to Neutral on August 19, 2026
• SectorHealthcare
• IndustryMedical Instruments & Supplies

AI analysis

Intuitive Surgical benefits from a dominant position in robot-assisted surgery with a durable recurring-revenue model tied to instruments, accessories, and service for a large installed base. Continued product innovation and expanding use-cases (including AI-enabled navigation and diagnostic adjacencies) provide clear growth levers, while healthy cash flow supports R&D and commercialization. Near-term market conditions are steady, and social/filing signals are neutral. Principal concerns include intensifying competition, payer/reimbursement pressure, regulatory hurdles, and valuation sensitivity that could amplify downside if growth decelerates.

Key factors

• Market leadership in robot-assisted surgery with a large installed base driving recurring consumables and service revenue
• High margins and strong cash-flow generation historically support reinvestment in R&D and new product development
• Ongoing product innovation and upgrades (next-gen systems, software/services) that can expand addressable procedures and drive attach rates
• Favorable readthrough from diagnostics/AI-enabled navigation advances that validate robotic and image-guided procedure adoption
• Stable near-term macro backdrop with balanced risk appetite among market participants, reducing likelihood of immediate demand shocks

Risks

• Competition from large medical device players (e.g., Medtronic, J&J) and new entrants that could pressure share or pricing
• Reimbursement pressure and payer-driven cost containment that could slow procedure volume growth or tighten hospital budgets
• Regulatory and approval risks for new systems and applications, plus potential post-market scrutiny or recalls
• High valuation sensitivity: growth misses or slower adoption would likely produce outsized stock downside
• Procedure-volume cyclicality and exposure to hospital capital spending; macro deterioration could reduce elective procedures
• Supply-chain or manufacturing constraints and potential litigation or product liability costs

Latest MarketMoodz coverage

• Intuitive Surgical Analysts Boost Forecasts After Strong Q1, Raise 2026 Guidance2026-04-22
• FDA Safety Alert on Intuitive Surgical Stapler Drives Hospital Shifts2026-03-19

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.